Company Hexima Limited




Biotechnology & Medical Research

Market Closed - Australian Stock Exchange 07:40:34 2023-12-07 pm EST Intraday chart for Hexima Limited 5-day change 1st Jan Change
0.018 AUD 0.00% -21.74% -10.00%

Business Summary

Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Plant-derived Proteins
100.0 %
6 100.0 % 1 100.0 % -74.45%

Sales per region

AUD in Million2022Weight2023Weight Delta
100.0 %
6 100.0 % 1 100.0 % -74.45%


Managers TitleAgeSince
Chief Executive Officer - 2014
Corporate Secretary - 2021

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer - 2014
Director/Board Member - 2018

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 167,039,629 60,411,535 ( 36.17 %) 0 36.17 %

Company contact information

Hexima Ltd.

La Trobe Institute for Molecular Sci La Trobe University

3086, Melbourne

address Hexima Limited(HXL)
As early as today, start finding the best investment opportunities!
Optimize my profits